Sciwind Biosciences signs $56 million deal with HK inno.N to treat metabolic diseases in South Korea


For the treatment of steatohepatitis associated with type 2 diabetes, obesity and metabolic dysfunction

Sciwind Biosciences Co., a clinical-stage biopharmaceutical company focused on developing treatments for metabolic diseases, and HK inno.N Corporation, a South Korean commercial-stage pharmaceutical company, announced the signing of a license and partnership agreement for development and commercialization ecnoglutide injection (XW003), a novel GLP-1 analog for the treatment of type 2 diabetes, obesity and metabolic dysfunction-associated steatohepatitis (MASH), South Korea.

Under the terms of the agreement, Sciwind Biosciences will receive an upfront payment and will be eligible to receive additional development, regulatory and commercial milestones in an amount up to $56 millionas well as up to double-digit royalties from future product sales.

HK inno.N Corporation will acquire exclusive rights to develop and commercialize ecnoglutide in South Korea. Sciwind Biosciences retains the rights to develop and commercialize ecnoglutide in all other global markets.

according to sea ​​saucer“GLP-1 analogs are a promising class of drugs that are suitable for a variety of indications,” said Dr. Sciwind Biosciences, founder and CEO. “Clinical trials of ecnoglutide have demonstrated strong efficacy in patients with both type 2 diabetes and obesity. therapeutic benefit, and satisfactory safety and tolerability.

Guo DawenCEO of inno.N Hong Kong said: “Ecnoglutide has demonstrated a strong and differentiated product profile in clinical studies, and we look forward to working with Sciwind to rapidly advance its development in clinical trials. South Korea.Based on the successful development and commercialization experience of our new gastroesophageal reflux disease drug K-CAB, we aim to make anoglutide the next over 100 billion won in Korea.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top